Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health*.
Dr. Reddy's Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
*IMS National Sales Perspective: Retail and Non-Retail MAT May 2018
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2319.6 as compared to the previous close of Rs. 2329.8. The total number of shares traded during the day was 55380 in over 3185 trades.
The stock hit an intraday high of Rs. 2398 and intraday low of 2303.55. The net turnover during the day was Rs. 128624394.